STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).
Be part of NHIF’s benchmarking program to collect industry-wide, standardized data to establish a national reference point for performance and clinical metrics.
NHIA sent a letter to HHS requesting that the agency make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs).
NHIF has adopted the Office of Management and Budget and Health and Human Services standard categories for race and ethnicity and urges all providers to include voluntary questions in their admissions process to capture this data.
On April 19, 2022, Baxter announced a supply disruption of the ExactaMix valve sets (ExactaMix 1200 Valve Set H938792 and ExactaMix 2400 Valve Set H938724) due to raw material constraints that are impacting production volumes. As a result, healthcare providers and institutions are driven to consider conservation measures when compounding using the ExactaMix Automated Compounder.
NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022, supporting amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it is in the patient’s best interest and weighing in on various other aspects of the bill.
NHIA has compiled product shortage recommendations to help clinicians manage patient care and conserve prefilled NS syringe supplies during this time when they may not be readily available.
The National Home Infusion Foundation (NHIF) is proud to announce the publication of the first issue of Infusion Journal. The new scholarly journal features independent research and studies related to infused therapies, patient outcomes, medication safety, economic analyses, and case studies.
The National Home Infusion Foundation (NHIF) is proud to announce that Mitra Gavgani, PharmD has joined its Board of Directors for the 2022-2023 term.
NHIA submitted comments on a CMS proposed rule: Medicare and Medicaid Programs; CY 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs, which would alter the way pharmacy price concessions, including direct and indirect remuneration (DIR fees), are calculated by pharmacy benefit managers (PBMs).
